219 related articles for article (PubMed ID: 21850490)
21. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Lin L; Yan M; Wu B; Lin R; Zheng Z
Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
[TBL] [Abstract][Full Text] [Related]
22. Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
Wang S; Hu LF; Zhang Y; Sun T; Sun YH; Liu SY; Ding JH; Wu J; Hu G
Neuropsychopharmacology; 2006 May; 31(5):933-40. PubMed ID: 16123757
[TBL] [Abstract][Full Text] [Related]
23. Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.
El Arfani A; Albertini G; Bentea E; Demuyser T; Van Eeckhaut A; Smolders I; Massie A
Neurochem Int; 2015 Sep; 88():88-96. PubMed ID: 26172319
[TBL] [Abstract][Full Text] [Related]
24. DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Sun SY; An CN; Pu XP
Brain Res Bull; 2012 Sep; 88(6):609-16. PubMed ID: 22664331
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D; Sherki Y; Melamed E; Fridkin M; Brenneman DE; Gozes I
Brain Res; 2000 Jan; 854(1-2):257-62. PubMed ID: 10784133
[TBL] [Abstract][Full Text] [Related]
26. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
Kopalli SR; Noh SJ; Koppula S; Suh YH
Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant effect of Spirulina (Arthrospira) maxima in a neurotoxic model caused by 6-OHDA in the rat striatum.
Tobón-Velasco JC; Palafox-Sánchez V; Mendieta L; García E; Santamaría A; Chamorro-Cevallos G; Limón ID
J Neural Transm (Vienna); 2013 Aug; 120(8):1179-89. PubMed ID: 23430275
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
29. The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.
Jia YJ; Deng JH; Zhang WZ; Sun ZL; Yang J; Yu Y; Gong XL; Jia J; Wang XM
CNS Neurosci Ther; 2017 Jan; 23(1):23-32. PubMed ID: 27412260
[TBL] [Abstract][Full Text] [Related]
30. Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.
Cass WA; Peters LE
Neurochem Int; 2010 Nov; 57(5):540-6. PubMed ID: 20615442
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Patricio F; Parra I; Martínez I; Pérez-Severiano F; Montes S; Aguilera J; Limón ID; Tizabi Y; Mendieta L
Neurotox Res; 2019 Apr; 35(3):699-710. PubMed ID: 30607904
[TBL] [Abstract][Full Text] [Related]
32. Early use of oleanolic acid provides protection against 6-hydroxydopamine induced dopamine neurodegeneration.
Mabandla MV; Nyoka M; Daniels WM
Brain Res; 2015 Oct; 1622():64-71. PubMed ID: 26111646
[TBL] [Abstract][Full Text] [Related]
33. Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.
Wree A; Mix E; Hawlitschka A; Antipova V; Witt M; Schmitt O; Benecke R
Neurobiol Dis; 2011 Feb; 41(2):291-8. PubMed ID: 20955797
[TBL] [Abstract][Full Text] [Related]
34. Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.
Haleagrahara N; Siew CJ; Ponnusamy K
J Toxicol Sci; 2013 Feb; 38(1):25-33. PubMed ID: 23358137
[TBL] [Abstract][Full Text] [Related]
35. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
36. Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease.
Wang J; Xu H; Jiang H; Du X; Sun P; Xie J
J Mol Neurosci; 2012 May; 47(1):113-9. PubMed ID: 22205146
[TBL] [Abstract][Full Text] [Related]
37. JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson's disease: Mitochondrial protection and antioxidant properties.
Fonseca-Fonseca LA; da Silva VDA; Wong-Guerra M; Ramírez-Sánchez J; Yaquis ASP; Ochoa-Rodríguez E; Verdecia-Reyes Y; de Araújo FM; Santana RC; Outeiro TF; Costa SL; Núñez-Figueredo Y
Neurotoxicology; 2021 Jan; 82():89-98. PubMed ID: 33232743
[TBL] [Abstract][Full Text] [Related]
38. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats.
Joo WS; Jin BK; Park CW; Maeng SH; Kim YS
Neuroreport; 1998 Dec; 9(18):4123-6. PubMed ID: 9926859
[TBL] [Abstract][Full Text] [Related]
39. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
40. Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression.
Dallé E; Daniels WM; Mabandla MV
Behav Brain Res; 2017 Jan; 316():189-196. PubMed ID: 27569183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
